肺癌市场规模、份额、成长分析、按诊断/治疗、按适应症、按最终用途、按地区 - 行业预测，2024-2031 年

2022年全球肺癌市场规模为294.5亿美元，从2023年的326.6亿美元成长到2031年的747.3亿美元，复合年增长率预计为10.9%。

全球肺癌市场是一个重要的医疗保健领域，专注于对公共卫生构成重大挑战的流行和致命疾病的诊断、治疗和管理。由于吸烟、环境污染物和遗传因素导致发病率上升，标靶治疗和免疫疗法等诊断和治疗方案的创新进步正在推动市场发展。从传统化疗到个人化和有效治疗的显着转变改善了患者的治疗效果，同时提高了对早期检测和预防措施的认识正在推动市场成长。儘管存在治疗成本和可及性等挑战，但正在进行的研究与人工智慧和巨量资料的整合有望彻底改变诊断和治疗策略，而这个不断发展的市场显示出患者照护改善和成长的巨大潜力。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 技术分析
• 监管分析
• 专利分析
• 案例研究分析
• 管道分析

肺癌市场规模：依诊断/治疗及复合年增长率（2024-2031）

• 市场概况
• 诊断
  • 支气管镜检查
  • TTNA
  • 影像
  • 肿瘤生物标记检测
  • 原位杂交
  • 其他的
• 治疗
  • 非侵入性
  • 免疫疗法
  • 标靶治疗
  • 微创
  • 射频消融术
  • 微波消融
  • 热凝固/冷冻疗法

肺癌市场规模：依适应症及复合年增长率（2024-2031）

• 市场概况
• 非小型基地台肺癌
• 小型基地台肺癌

肺癌市场规模：依最终用途及复合年增长率（2024-2031）

• 市场概况
• 医院
• 诊断实验室
• 影像诊断中心
• 学术界
• 专科诊所

肺癌市场规模及复合年增长率（2024-2031）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• F. Hoffmann-La Roche（Switzerland）
• AstraZeneca（UK）
• Sanofi（France）
• Pfizer, Inc.（US）
• Bristol-Myers Squibb Company（US）
• Sysmex Corporation（Japan）
• Thermo Fisher Scientific（US）
• Qiagen（Germany）
• Janssen Pharmaceuticals（US）
• Quest Diagnostics（US）
• Takeda Pharmaceutical Company（Japan）
• Novartis AG（Switzerland）
• Eli Lilly & Company（US）
• Merck & Co., Inc.（US）
• Boehringer Ingelheim（Germany）
• Merck KGaA（EMD Serono）（Germany）
• AbbVie（US）
• Astellas Pharma（Japan）
• GlaxoSmithKline（UK）
• Johnson & Johnson（US）

结论和建议

Global Lung Cancer Market size was valued at USD 29.45 billion in 2022 and is poised to grow from USD 32.66 billion in 2023 to USD 74.73 billion by 2031, growing at a CAGR of 10.9% during the forecast period (2024-2031).

The global lung cancer market represents a vital healthcare sector focused on diagnosing, treating, and managing a prevalent and lethal disease that poses significant public health challenges. With rising incidences primarily attributed to smoking, environmental pollutants, and genetic factors, the market is fueled by innovative advancements in diagnostic and therapeutic options, such as targeted therapies and immunotherapies. A notable shift from traditional chemotherapy to personalized and effective treatments enhances patient outcomes, while increased awareness of early detection and preventative measures drives market growth. Despite challenges like treatment costs and accessibility, ongoing research, alongside the integration of artificial intelligence and big data, promises to revolutionize diagnosis and therapeutic strategies, showcasing significant potential for improved patient care and growth within this evolving market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lung Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lung Cancer Market Segmental Analysis

Global Lung Cancer Market is segmented by diagnostics, indication, end-use and region. Based on diagnostics, the market is segmented into diagnostics and therapy. Based on indication, the market is segmented into non-small cell lung cancer and small cell lung cancer. Based on end-use, the market is segmented into hospitals, diagnostic laboratories, diagnostic imaging centers, academia, specialty clinics, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Lung Cancer Market

A significant catalyst for the global lung cancer market is the relentless progress in medical research and technology. The growing comprehension of lung cancer biology, alongside breakthroughs in diagnostic tools, targeted therapies, immunotherapies, and precision medicine, is propelling market growth. These innovations not only introduce novel treatment alternatives but also enhance patient outcomes and facilitate early detection. The shift towards personalized treatment strategies allows healthcare providers to tailor interventions to individual patient profiles, further driving the demand for advanced lung cancer therapies. Consequently, these technological advancements are pivotal in shaping the future landscape of the lung cancer treatment market.

Restraints in the Global Lung Cancer Market

One of the main challenges facing the global lung cancer market is the exorbitant cost associated with treatments. Patients often confront substantial financial burdens due to the high prices of lung cancer therapies, such as targeted treatments and immunotherapies. This issue can severely limit patient access to these advanced options, particularly in areas with limited healthcare resources or insufficient insurance coverage. Consequently, the overall affordability and accessibility of lung cancer treatments create significant obstacles that can impede the market's growth and hinder the provision of equitable care to patients, ultimately affecting the broader adoption of essential therapies.

Market Trends of the Global Lung Cancer Market

The global lung cancer market is witnessing a significant trend towards precision medicine and targeted therapies, driven by advancements in genomic research and molecular characterization of tumors. This shift fosters the development of personalized treatment regimens that specifically address genetic mutations and biomarkers unique to each patient. As healthcare systems prioritize improved treatment outcomes and reduced adverse effects, the demand for tailored therapies is surging. Furthermore, the integration of molecular profiling techniques is enhancing the efficacy of treatments, promising better patient care and prognosis. This evolution not only reshapes therapeutic approaches but also amplifies the potential for innovation in lung cancer management globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Study Analysis
• Pipeline Analysis

Global Lung Cancer Market Size by Diagnostics & Therapy & CAGR (2024-2031)

• Market Overview
• Diagnostics
  • Bronchoscopy
  • TTNA
  • Imaging
  • Tumor Biomarker Test
  • In Situ Hybridization
  • Others
• Therapy
  • Non-Invasive
  • Immunotherapy
  • Targeted Therapy
  • Minimally Invasive
  • Radiofrequency Ablation
  • Microwave Ablation
  • Thermal/Cryoablation

Global Lung Cancer Market Size by Indication & CAGR (2024-2031)

• Market Overview
• Non-Small Cell Lung Cancer
• Small Cell Lung Cancer

Global Lung Cancer Market Size by End-Use & CAGR (2024-2031)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Diagnostic Imaging Centers
• Academia
• Specialty Clinics

Global Lung Cancer Market Size & CAGR (2024-2031)

• North America (Diagnostics & Therapy, Indication, End-Use)
  • USA
  • Canada
• Europe (Diagnostics & Therapy, Indication, End-Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnostics & Therapy, Indication, End-Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnostics & Therapy, Indication, End-Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnostics & Therapy, Indication, End-Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• F. Hoffmann-La Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly & Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (EMD Serono) (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations